Mealey's (August 6, 2015, 10:37 AM EDT) -- WASHINGTON, D.C. — A Texas federal judge did not err in holding various claims of several patents covering the glaucoma drug Lumigan not invalid as obvious or for lack of enablement and written description, the Federal Circuit U.S. Court of Appeals concluded Aug. 4 (Allergan Inc. v. Sandoz Inc., et al., No. 14-1275, Fed. Cir.)....